Details
| Originalsprache | Englisch |
|---|---|
| Seiten (von - bis) | 128-131 |
| Seitenumfang | 4 |
| Fachzeitschrift | Graft |
| Jahrgang | 5 |
| Ausgabenummer | 3 |
| Publikationsstatus | Veröffentlicht - 2002 |
| Extern publiziert | Ja |
Abstract
The persistence of chronic renal allograft nephropathy is an important cause of graft loss. Here the authors describe the 1st long-term results after switching from cyclosporin A (CyA) to tacrolimus in patients with chronic allograft nephropathy. Eighteen patients had chronic allograft nephropathy confirmed by biopsy. Mean observation period was 12.3 months. The mean rate of decline in glomerular filtration (1/serum creatinine × 100/year) was measured as a function of time before and after conversion therapy using linear regression analysis. The regression coefficients were compared using the Student t-test for paired samples. Conversion to tacrolimus significantly reduced the progression to kidney failure. Kidney function was stable in the observed time interval as the mean change of glomerular filtration rate decelerated significantly (1/creatinine per year × 100, P < 0.029). Lipids and blood pressure values were significantly lowered after conversion therapy. The authors' results suggest that switching from CyA to tacrolimus is adequate for treating chronic rejection in kidney allograft recipients.
ASJC Scopus Sachgebiete
- Medizin (insg.)
- Transplantationsmedizin
Zitieren
- Standard
- Harvard
- Apa
- Vancouver
- BibTex
- RIS
in: Graft, Jahrgang 5, Nr. 3, 2002, S. 128-131.
Publikation: Beitrag in Fachzeitschrift › Artikel › Forschung › Peer-Review
}
TY - JOUR
T1 - Successful conversion of immunosuppressives from cyclosporine to tacrolimus in chronic rejection after kidney transplantation
AU - Blume, Cornelia
AU - Hollenbeck, Markus
AU - Ivens, Katrin
AU - Heering, Peter
AU - Hetzel, Gerd Rüdiger
AU - Grabensee, Bernd
PY - 2002
Y1 - 2002
N2 - The persistence of chronic renal allograft nephropathy is an important cause of graft loss. Here the authors describe the 1st long-term results after switching from cyclosporin A (CyA) to tacrolimus in patients with chronic allograft nephropathy. Eighteen patients had chronic allograft nephropathy confirmed by biopsy. Mean observation period was 12.3 months. The mean rate of decline in glomerular filtration (1/serum creatinine × 100/year) was measured as a function of time before and after conversion therapy using linear regression analysis. The regression coefficients were compared using the Student t-test for paired samples. Conversion to tacrolimus significantly reduced the progression to kidney failure. Kidney function was stable in the observed time interval as the mean change of glomerular filtration rate decelerated significantly (1/creatinine per year × 100, P < 0.029). Lipids and blood pressure values were significantly lowered after conversion therapy. The authors' results suggest that switching from CyA to tacrolimus is adequate for treating chronic rejection in kidney allograft recipients.
AB - The persistence of chronic renal allograft nephropathy is an important cause of graft loss. Here the authors describe the 1st long-term results after switching from cyclosporin A (CyA) to tacrolimus in patients with chronic allograft nephropathy. Eighteen patients had chronic allograft nephropathy confirmed by biopsy. Mean observation period was 12.3 months. The mean rate of decline in glomerular filtration (1/serum creatinine × 100/year) was measured as a function of time before and after conversion therapy using linear regression analysis. The regression coefficients were compared using the Student t-test for paired samples. Conversion to tacrolimus significantly reduced the progression to kidney failure. Kidney function was stable in the observed time interval as the mean change of glomerular filtration rate decelerated significantly (1/creatinine per year × 100, P < 0.029). Lipids and blood pressure values were significantly lowered after conversion therapy. The authors' results suggest that switching from CyA to tacrolimus is adequate for treating chronic rejection in kidney allograft recipients.
UR - http://www.scopus.com/inward/record.url?scp=0036250647&partnerID=8YFLogxK
U2 - 10.1177/1522162802005003002
DO - 10.1177/1522162802005003002
M3 - Article
AN - SCOPUS:0036250647
VL - 5
SP - 128
EP - 131
JO - Graft
JF - Graft
SN - 1522-1628
IS - 3
ER -